Lymphedema/elephantiasis – The eradication of elephantiasis by controlling lymphedema at all clinical stages The proposal of the Godoy & Godoy International School of Lymphatic Therapy is to eradicate clinical stage III lymphedema (elephantiasis) over the next few years.

The Godoy & Godoy International School of Lymphatic Therapy has published a large number of articles that show a significant advance in the treatment of lymphedema, even in clinical stage III (elephantiasis). In September 2017, at the World Congress of Lymphology in Barcelona, the Godoys demonstrated the possibility of normalization or near normalization of all clinical stages including elephantiasis. This provides new prospects to treat millions of people all around the world. There are about 16 million people who have clinical stage III lymphedema (elephantiasis), most of whom have no hope of therapy.

The proposal of the Godoy & Godoy International School of Lymphatic Therapy is to eradicate clinical stage III lymphedema (elephantiasis) over the next few years. The plan is to train professionals initially to control clinical stage I disease, a condition that does not require much technical knowledge but often evolves to clinical stage II. Simultaneously, the school intends to produce better-qualified professionals to treat clinical stage II lymphedema, thereby prevent this phase from evolving to elephantiasis.

With government support, one of the objectives of the school is to create exemplary centers with trained professionals in every country to treat cases of elephantiasis. Thus, the Godoy & Godoy International School of Lymphatic Therapy proposes to help millions of people to prevent the development of advanced stages of the disease and treat elephantiasis, with the help of interested governments and the World Health Organization (WHO).

The deterioration in the quality of life of these people is appalling, but their lives can be improved radically with treatment. Furthermore, the very high social cost can be reduced considerably with treatment. It is important to remember that lymphedema mainly affects the most disadvantaged populations and thus the support of governments and the WHO is fundamental. No human being wants to be excluded from his or her activities due to disease and so preventive practical actions are needed to keep this population part of the active society.

Feel free to contact us for further information and to make this a reality.